Clinical Trial Update: Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and efficacy of Carbocisteine in treating non-alcoholic fatty liver disease; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-alcoholic Fatty Liver Disease

Drugs mentioned

• Carbocisteine (carbocisteine)

Snippet

Sponsor: Tanta University | Conditions: Non-Alcoholic Fatty Liver Disease | Phase 2 | Status: RECRUITING